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2009;28:954-959.The Incidence of Veno-Occlusive Disease Following
Allogeneic Hematopoietic Stem Cell Transplantation
Has Diminished and the Outcome Improved over the
Last Decade
Enric Carreras, Marina Dıaz-Beya, Laura Rosi~nol, Carmen Martınez,
Francesc Fernandez-Aviles, Montserrat RoviraThe evolution of the incidence, morbidity, and mortality of veno-occlusive disease (VOD) was analyzed in
845 allogeneic hematopoietic stem cell transplantations (allo-HSCTs) performed over 24 years. A total of
117 patients and 73 patients developed VOD following the Seattle and the Baltimore diagnostic criteria,
respectively (cumulative incidence 13.8% and 8.8%). The cumulative incidence was significantly higher in
the period 1985 to 1996 than in 1997 to 2008 (11.5% vs 6.5%; P 5 .01). This decline was because of the
low incidence of VOD among reduced-intensity conditioning-HSCT (RIC-HSCT) (2.1%) and the reduction
among those receiving myeloablative-HSCT from unrelated donors (32.7% vs 10.5%, P5 .001). A total of 35
patients had severe VOD (26 with multiorgan failure [MOF]), and 20 died by VOD (cumulative mortality rate’Investigacions Biomediques Agustı Pi i Sunyer (IDIBAPS), Univer-
matologyDepartment, Hospital Clınic, Institut d’Investigacions Bio-
larroel 170, 08036 Barcelona, Spain (e-mail: carreras@clinic.ub.es).
1714 Biol Blood Marrow Transplant 17:1698-1720, 2011E. Carreras et al.17.3%, Seattle, or 22.5%, Baltimore). The mortality declined since 1997 (from 22% to 9%; P5.06, Seattle, and
from 36% to 14%; P5 .04, Baltimore), with the introduction of defibrotide being the only relevant change in
the management of patients. This occurred even though the severity of VOD was similar in both periods.
Among those with MOF, only 2 of 8 (25%) receiving defibrotide died versus 14 of 18 (78%) receiving other
treatments (P 5 .007). Myeloablative conditioning, previous liver disease, poor performance status, and al-
ternative donors were the variables with higher impact on VOD development. In summary, although
VOD remains a dreaded early complication of HSCT, technical and therapeutic progress in recent decades
have notably reduced its incidence and improved the outcome.
Biol Blood Marrow Transplant 17: 1713-1720 (2011)  2011 American Society for Blood and Marrow TransplantationKEYWORDS: Veno-occlusive disease, Sinusoidal obstruction syndrome, Allogeneic stem cell transplantation,
Early complication of SCT, DefibrotideINTRODUCTION
Hepatic sinusoidal obstruction syndrome, com-
monly know as veno-occlusive disease (VOD) of the
liver, is an early complication of hematopoietic stem
cell transplantation (HSCT). This syndrome is charac-
terized by clinical features of rapid weight gain, ascites,
painful hepatomegaly, and jaundice [1,2].
As with any syndrome, the diagnosis of VOD is
based on clinical criteria and does not require histologic
or hemodynamic confirmation. The diagnostic criteria
described by the Seattle group [3] are the most widely
used, even though those described by the Baltimore
group [4] permit a more precise diagnosis. The clinical
course of VOD is usually self-limiting, but severe cases
result in a very high mortality rate [5]. There is no con-
sensus on a suitable grading system for the severity of
this syndrome.Usually, it is classified asmild,moderate,
or severe retrospectively, based on its evolution [6].
Given the absence of predictable models applicable to
all cases, most authors consider that the evolution to
multiorgan failure (MOF) is the most reliable marker
of severity and predictor of poor outcome [5].
Several patient- and transplant-related risk factors
have been associated with VOD, with the most impor-
tant being the disease and the liver status, the type of
HSCT, and the intensity of the cytoreductive therapy
used in the conditioning regimen [1,2,4,7,8]. The
incidence of VOD rarely exceeds 5% in patients
receiving an autologous HSCT but can be observed
in up to 60% of patients after allogeneic HSCT
(allo-HSCT). A prospective study performed by the
European Group for Blood and Marrow
Transplantation (EBMT) showed that the presence
of several risk factors have an additive effect on the
incidence of VOD [8]. This fact and the use of differ-
ent diagnostic criteria explain why the incidence of
VOD ranges from 0% to 60% in the published series.
Recently, a well-conducted retrospective review of
135 studies performed between 1979 and 2007 showed
that the mean incidence of VOD was 13.7% (17.3%
and 9.6% using the Seattle and Baltimore criteria,
respectively). This incidence was lower in the period1979 to 1994 than between 1994 and 2007 (11.5% vs
14.6%; P \ .05). The mortality rate from severe
VOD was 84.3%, mostly occurring in patients with
MOF. The authors concluded that the incidence of
VOD was lower than that observed in some early
reports, and it did not decrease over the years despite
the recent introduction of the reduced-intensity
conditioning (RIC) to prepare patients undergoing
allo-HSCT.
After considering these results, we decided to analyze
our series of patients receiving allogeneic HSCT, as our
feelingwas that the incidence ofVODhas been declining
and its outcome improving over the years. Our
institution has a large and prolonged experience in the di-
agnosis andmanagement of this complication [7-12]. For
that reason, we were able to analyze a homogeneous and
carefully evaluated series of 845 consecutive cases of
allo-HSCT performed during the last 24 years.PATIENTS AND METHODS
Between January 1985 and July 2008, 845 allo-
HSCT procedures were performed on 763 patients
in our unit. The main characteristics of the patients
and the most relevant aspects of HSCT are shown in
Table 1. Briefly, their median age was 36 years and
slightly more than one-half (58%) were men. Primary
diseases were acute myelogenous or lymphoblastic
leukemia (n 5 363), chronic myelogenous leukemia
(CML) (n 5 238), myelodysplastic syndrome (MDS)
(n 5 55), non-Hodgkin and Hodgkin’s lymphomas
(n 5 75), multiple myeloma (MM) (n 5 41), chronic
lymphocytic leukemia (CLL) (n 5 33), and severe
aplastic anemia (SAA) (n 5 31). Malignancies were in
early (first complete remission [CR] or a chronic phase
[CP]), intermediate ($2 CR or second CP or acceler-
ated phase), or advanced phases in 46%, 17%, and
37% of cases, respectively. Performance status was
good (Karnofsky score $90) in 71% of HSCT. Ten
percent and 6% of the patients had a previous liver
disease (viral infection or infiltrative) or increased
levels of alanine transaminase at HSCT, respectively.
Table 1. Patients and Transplantation Characteristics
Period Analyzed January 1985-August 2008
HSCT analyzed 845 (763 patients)
Sex Male 492 (58%), female 353 (42%)
Median age (range) 35.8 (4-67)
Underlying
disease
ALL 148 (18%)/AML 215 (25%)/MDS 55
(7%)/CML 238 (28%)/NHL 60 (7%)/MM
41 (5%)/CLL 33 (4%)/SAA 31 (4%)/HL
15 (2%)/other 8 (1%)
Disease status at HSCT
(malignancies)
Early: 373 (46%)
Intermediate: 142 (17%)
Advanced: 298 (37%)
Karnofsky index $90: 604 (71%)/<90: 241 (29%)
Previous liver disease 87 (10.3%)
[ Transaminases
at HSCT
54 (6.4%)
Year of HSCT 1985 to 1996: 393 (47%)
1997 to 2008: 452 (53%)
Conditioning regimen CyTBI #12 Gy or BuCy: 530 (63%)
CyTBI >12 Gy or BuCy + others):
129 (15%) Fluda (±Bu, Mel, TBI2
Gy or IDA): 134 (16%)
Cy (±ATG or TNI): 32 (4%)
Others (BEAM or similar): 20 (2%)
Intensity of conditioning Myeloablative: 695 (82%)/RIC: 150 (18%)
TBI ($10 Gy) or Bu
(16 mg/kg) in
conditioning
TBI: 584 (69%)/Bu: 63 (7%)
GVHD prophylaxis None: 8 (1%)/CyA (±PDN): 274 (32%)
CyA + MTX: 460 (54%)/CyA + MMF:
103 (12%)
T cell depletion MoAb: 25 (3%)/Elutriation: 29 (3%)/CD34+
selection: 111 (13%)/ATG: 49 (6%)
Donors HLA identical sibling: 648 (77%)
Other relatives: 28 (3%)
Unrelated: 169 (20%)
Stem cell source BM: 421 (62%)/PB: 407 (46%)/CB: 17 (2%)
Second HSCT 123 (15%) (after auto 61-7%)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myelogenous leukemia; MDS, myelodisplastic
syndrome; NHL, non-Hodgkin lymphoma; HL, Hodgkin’s lymphoma;
MM, multiple myeloma; CLL, chronic lymphocytic leukemia; SAA,
severe aplastic anemia (n 5 31); Fluda, fludarabine; Cy, cyclophospha-
mide; Bu, busulfan; Mel, melphalan; TBI, total body irradiation; ATG,
antithymocyte globulin; BEAM, carmustine + etoposide + cytarabine
+ melphalan; RIC, reduced-intensity conditioning; CyA, cyclosporine
A; MTX, methotrexate; MMF mycophenolate mofetil; MoAb, monoclo-
nal antibodies; BM, bone marrow; PBSC, peripheral blood stem cells;
CB, cord blood.
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(Cy) 120 mg/kg1 total body irradiation (TBI)—from
10 Gy in a single dose to 13.5 Gy in 4 fractions—
(69%), fludarabine 1 others (16%), or busulfan (Bu)
16 mg/kg 1 Cy 120 mg/kg (7%). In 18% of HSCT,
we used an RIC. The stem cell source was bone mar-
row in 62% of cases, mobilized peripheral blood in
46%, and umbilical cord blood in 2%. Cyclosporine
and short methotrexate (54%), prednisone (32%), or
mycophenolate (12%) where mainly used for graft-
versus-host disease (GVHD) prophylaxis. Ex vivo
T cell depletion was performed in 19% of transplanta-
tions using different methods, and 6% received antith-
ymocyte globulin (ATG). Alternative donors were
used in 197 cases (23%), and 123 patients had received
a previous autologous (n5 61) or allo-HSCT (n5 62).All patients were housed in HEPA/LAF rooms
during the neutropenic phase and received the foll-
owing prophylaxis: mesna (Cy-containing regimes),
phenytoin (Bu-containing regimes), quinolones and
acyclovir (during neutropenia), fluconazole (up to day
160 followingHSCT), and cotrimoxazole or inhalated
pentamidine. We do not use pharmacologic measures
routinely for VOD prophylaxis, but, occasionally,
some individually selected patients with several risk
factors for this complication (usually second trans-
plants performed early after the first HSCTwith a pre-
vious liver disease) received low-molecular-weight
heparin (LMWH) during conditioning and up to day
114. No patients received ursodeoxycholic acid.Definition of VOD and Its Severity and
Management
Diagnosis of VOD was established using both
Seattle and Baltimore clinical criteria [4,6]
whenever these clinical data could not be attributed
to other causes such as sepsis, drug toxicity, or heart
failure. Based on previous observations by our
group [12], we did not limit this diagnosis to the clas-
sical 21 days after HSCT, and all suspicious cases
appearing in the first 60 days were evaluated. The se-
verity of VOD was classified retrospectively using
a modified Seattle definition. When all the signs and
symptoms of VOD disappeared without treatment
or only with fluid and sodium restriction and di-
uretics, VODwas considered ‘‘mild.’’ Patients requir-
ing other therapeutic interventions were classified as
having ‘‘moderate’’ VOD. Those cases not resolved
by day 1100, those who died before this date with
an active VOD, or in whom death was directly attrib-
utable to VOD were considered to have ‘‘severe’’
VOD. Additionally, the presence of MOF (renal,
respiratory, or central nervous system dysfunction
clearly related with VOD) was enough to consider
the episode as a ‘‘severe’’ episode.
After our initial studies [9,10], in which patients were
evaluated prospectively by means of a transjugular
approach, we only used this technique to confirm the
origin of the liver disturbance before adopting any
therapeutic measures that could be hazardous to the
patient. As VOD is a syndrome, in any case we used
the result of hemodynamic study to establish or
modify this diagnostic.
Patients with VOD were treated with sodium and
fluid restriction, diuretics, and if progressing, dopa-
mine, sodium heparin, LMWH, or recombinant tissue
plasminogen activator depending on the severity.
Since 2000, patients with a VOD that fulfilled the
Baltimore criteria received defibrotide (DF) (provided
by Gentium S.p.A., Como, Italy) for compassionate
purposes at a dose of 10 mg/kg every 6 hours intrave-
nously for a minimum of 14 days.
Table 2. Main Characteristics of the VOD Cases
Seattle Criteria Baltimore Criteria
VOD cases 117/845 73/845
Cumulative incidence of VOD 13.8% ± 1% 11.5% ± 1%
Diagnostic data; median (range) Day +9 (0-44) Day +8 (0-44)
Number of clinical criteria (2:49*/3:68) (3:57/4:16)
Clinical data: weight gain 115 73
Painful hepatomegaly 73 68
Ascites 21 21
Hyperbilirubinemia 114 73
MOF 26 (2.2) 26 (3.6)
Hemodynamic study 49 33
Mild-moderate VOD 79 (67.5) 38 (52)
Survived >+100 without VOD 56 (47.8) 31 (42.5)
Died <+100 without VOD 23 (19.7) 7 (27.4)
IP 9 1
Infection 5 2
GVHD 3 2
Graft failure 3 1
Relapse 2 1
Hemorrhage 1 —
Severe VOD [with MOF] 38 [26] (33) 35 [26] (48)
Died due to VOD 20 (19.7) 20 (27.4)
Died before +100 with VOD 7 5
Graft failure 3 3
Infection 3 1
GVHD 1 1
Died before +100 without VOD 3 3
IP 2 2
Infection 1 1
Alive >+100 without VOD 8 (6.8) 7 (9.6)
Mortality rate due to VOD (†)
Whole series 17% ± 3% 27 ± 5%
<year 1997 17/72 (22% ± 5%) 17/44 (36% ± 7%)
$year 1997 3/45 (9% ± 4%) 3/29 (14% ± 6%)
P value 0.06 0.04
MOF indicates multiorgan failure; IP, interstitial pneumonitis; GVHD,
graft-versus-host disease, VOD, veno-occlusive disease.
In ( ) percentages.
*Only 5 of these patients fulfill the Baltimore criteria.
†Cumulative incidence.
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The incidence of VODafter transplantationwas cal-
culated using cumulative incidence (CumI) curves in
a competing risks setting, with death being treated as
a competing event toVOD. In the population of patients
having experienced VOD, the incidence of death from
VODwas also estimated by cumulative incidence curves
from the date of diagnosis of VOD; the competing event
was death up to day 1100 from another cause. Univar-
iate analyses were performed using Gray’s test. Multiple
comparisons on cumulative incidence of VOD in differ-
ent subgroups of patients were taken into account using
the Bonferroni correctionwithP\ .016. Statistical anal-
yses will be performed with TIBCO Spotfire S1 8.1
(TIBCO Software Inc. Palo Alto, CA) for Windows
software package.
Risk factors for VOD included in the uni- and mul-
trivariate analysis were age, sex, underlying disease,
status of the disease at HSCT (early, intermediate, ad-
vanced), Karnofsky status at HSCT ($90 vs\90), pre-
vious liver disease, increased transaminase levels at
HSCT, year of HSCT, transplantation number (firstvs subsequent), conditioning intensity (myeloablative
conditioning [MAC] vs RIC), conditioning agents (Bu-
containing vs others; TBI$10 cGy vs non-TBI; fludar-
abine vs others), GVHD prophylaxis (methotrexate vs
mycophenolate vs others), ex vivo T cell depletion,
source of stem cells (bone marrow [BM], peripheral
blood, cordblood), typeofdonor (HLAidentical sibling,
other family members, unrelated), VOD prophylaxis,
and use of ATG. To compare dichotomous variables,
the Fisher (2-tailed) and chi-square tests were used for
univariate analysis. Logistic regression was performed
and included all variables that were significant in univar-
iate (p\0.05), and a backward stepwise selection (Wald)
was used to identify the final model. Results were
expressed as odds ratios (OR) and 95%confidence inter-
vals (CI). These analyses were performed using SPSS
Statistics version 17.0.0 (SPSS, Inc, Chicago, IL), and
grouped numerical data were expressed as mean 6
standard deviation where appropriate.RESULTS
One hundred seventeen and 73 patients developed
a VOD following the Seattle and the Baltimore diag-
nostic criteria. This represents a CumI of 13.8%6 1%
and 8.8% 6 1%, respectively. Their main clinical
characteristics are shown in Table 2. Only 1 patient
developed VOD after the classical day 121
(day144). Forty-four patients only fulfilled the Seattle
diagnostic criteria; none of them developed MOF or
had a severe VOD. Weight gain and jaundice were
the most usual clinical manifestations (almost 100%
of patients); 26 developed MOF (renal failure in 16,
pulmonary in 20, and neurologic in 5).
When comparing the CumI of VOD using Balti-
more criteria in the 3 main groups of HSCT cases
(Table 3)—(1) MAC before 1997 (n 5 385); (2)
MAC since 1997 (n 5 310); and (3) RIC since 1997
(n 5 142)—we observed that in the whole series the
CumI of VOD was higher in the period 1985 to
1996 than in 1997 to 2008 (11.5% 6 2% vs 6.5% 6
1%; P 5 .01). This difference was mainly because of
the increasing numbers of RIC-HSCT cases in the
second period with a CumI of VOD of 2.1% 6 1.2%
(vs 8.4% 6 1.6% in MAC since 1997; P5 .011). Sim-
ilar results were obtained when we performed the
same analysis in patients receiving an HSCT from
HLA-identical siblings. However, when we analyzed
patients receiving an HSCT from alternative donors,
we additionally observed a clear reduction on the inci-
dence of VOD when comparing those receiving
a MAC-HSCT before or since 1997 (32.7% 6 7% vs
10.5% 6 3%; P 5 .002). In this subgroup of
patients, the incidence of VOD among those receiving
an RIC-HSCT was similar to that observed among
those receiving a MAC-HSCT (7.6% 6 4% vs
10.5% 6 3%; not significant, ns).
Table 3. VOD Incidence Using Baltimore Criteria in the Different Subgroups of Patients Analyzed
Year HSCT <1997 $1997
Type HSCT
(a) MAC (b) MAC (c) RIC
VOD/Total CumI VOD/Total CumI VOD/Total CumI
Whole series 44/385* 12% ± 2% 26/310 8% ± 2% 3/142 2% ± 1%
P value a versus b 5 0.19 b versus c 5 0.011 a versus c 5 0.0007
HLA 5 sibling 29/335* 9% ± 1% 15/204 7% ± 2% 0/103 0
P value a versus b 5 0.61 b versus c 5 0.005 a versus c 5 0.002
Unrelated 15/50* 33 ± 7 11/106 11% ± 3% 3/39 8% ± 4%
P value a versus b 5 0.002 b versus c 5 0.56 a versus c 5 0.005
CumI indicates cumulative incidence; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning, HSCT, hematopoietic stem cell
transplantation.
*Eight patients receiving an RIC-HSCT before 2007 were excluded.
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2000, patients with a severe VOD were treated as
follows: dopamine perfusion (11 cases); hemodialysis
(2 cases); transjugular intrahepatic portosystemic shunt
(3 cases); heparin (3 cases); or recombinant tissue plas-
minogen activator (2 cases). Since 2000, 19 patients
with a VOD fulfilling the Baltimore criteria were
treated with DF.
Because it was included in our early studies or be-
cause of doubts regarding the differential diagnosis,
a hemodynamic study of the liver was performed in
49 patients (42%). The hepatic venous gradient pres-
sure (HVGP) was $10 mmHg in 11 patients (22%)
(17 6 7 mmHg). Of them, 5 died because of VOD
and3 died before day1100because of interstitial pneu-
monia 6 GVHD. None of the 38 patients with an
HVGP lower than 10 mmHg (5 6 2 mmHg) died as
a consequence of VOD, but 12 died early after HSCT
because of interstitial pneumonia (n 5 7), GVHD
(n 5 2), infection (n5 2), or graft failure (n 5 1).
In 79 (Seattle) or 38 (Baltimore) cases, VOD had
a mild or intermediate severity and resolved by day
1100. Of these, 23 died early after HSCT (before day
1100) because of intercurrent complications (mainly
interstitial pneumonitis and infections) (Table 2).
Thirty-eight (Seattle) or 35 (Baltimore) patients had se-
vere VOD (26 with MOF). In 20 of these patients, the
death was clearly attributable to VOD. This represents
aCumIofdeath fromVODof17%6 3%or27%6 5%
using Seattle or Baltimore criteria, respectively. Only 8
(Seattle) or 7 (Baltimore) resolved their VOD and sur-
vived .100 days. The remaining cases died because of
intercurrent causes with or without an active VOD
(Table 2). In summary, 64 (Seattle) or 38 (Baltimore)
patientswithVODsurvived after day1100; the remain-
ing had died of VOD (20 cases) or because of intercur-
rent complications during this period (27 [23.1%] and
15 [20.5%] in the Seattle and Baltimore groups, respec-
tively), mainly interstitial pneumonia, infection, or graft
failure.When comparing patients treated up to or since
1997, we observed that the CumI of dying from
VOD was 22% 6 5% versus 9% 6 4% (Seattle; P 5
.06) and 36% 6 7% versus 14% 6 6% (Baltimore; P
5 .04), respectively. This occurred even though the se-
verity of VOD was similar in both periods with 25%
versus 18% (Seattle; ns) and 41% versus 28% (Balti-
more; ns) of cases evolving to MOF. When analyzing
the subgroup of patients with MOF receiving or not
DF, we observed a clear reduction of patients dying
from VOD (2 of 8 [25%] DF versus 14 of 18 [78%]
other treatments [P 5 .007]).
Univariate analysis including all relevant
variables showed that those factors with an adverse
impact on the incidence of VOD were as follows
(Table 4): HSCT performed before 1997 (P 5 .014);
a diagnosis of CML (P 5 .053); MAC (P 5 .001);
alternative donors (P 5 .001); use of BM (P 5 .025);
T cell-repleted graft (P 5 .017); abnormal liver and/
or transaminase levels before HSCT (P 5 .001 and
P 5 .004, respectively); and a Karnofsky index \90
(P 5 .02). In the multivariate analysis, only CML
(OR 5 1.96; 95% CI 5 1.1-3.6), MAC (OR 5 7.99;
95% CI 5 2.3-28), alternative donors (OR 5 3; 95%
CI 5 1.7-5.4), previous liver disease (OR 5 3.4;
95% CI 5 1.7-6.6), and poor performance status
(OR 5 3.2; 95% CI 5 1.8-5.7) retained statistical
significance.DISCUSSION
To our knowledge, this is the largest series from
a single center focused on the analysis of this early
complication of HSCT. The most relevant aspect of
our cohort was its homogeneity. All HSCT procedures
were made following very similar guidelines for trans-
plantation, and the diagnoses and management of
VOD were done by a group of physicians and nurses
focused on the study of this complication since 1985.
Table 4. Univariate and Multivariate Analysis Using Baltimore Criteria
Adverse Favorable VOD/Total (%) Baltimore Univariate Multivariate Odds Ratio 95% CI
<1997 44/393 (11.2) 0.014
$1997 29/452 (6.4)
CML 28/238 (11.8) 0.053 0.031 1.96 1.06-3.61
Other diagnosis 45/607 (7.4)
MAC 70/695 (10.1) 0.001 0.001 7.99 2.27-28.05
RIC 3/150 (2.0)
Other donors 29/197 (14.7) 0.001 <0.001 3.00 1.68-5.35
HLA 5 sibling 44/648 (6.8)
BMSC 46/421 (10.9) 0.025
PBSC 25/407 (6.1)
Non-CD34+ select 70/734 (9.5) 0.017
CD34+ selection 3/111 (2.7)
Previous liver disease 17/87 (19.5) 0.001 <0.001 3.35 1.71-6.58
Normal liver 56/756 (7.4)
[ ALATat HSCT 11/54 (20.4) 0.004
Normal ALAT 62/789 (7.9)
Karnofsky <90 29/235 (12.3) 0.020 <0.001 3.18 1.77-5.71
Karnofsky $90 43/599 (7.2)
CML indicates chronic myelogenous leukemia; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; BMSC, bone marrow stem cells;
PBSC, peripheral blood stem cells; ALAT, alanin aminotransferase; HSCT, hematopoietic stem cell transplantation.
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rized in 4 points.
1. The incidence of VOD: As observed in the EBMT
prospective study [8] and in the recent analysis of all
published reports including more than 50 patients
[5], the mean incidence of VOD seemed to be lower
than published in early reports (around 9% using
the Baltimore criteria and 14% with the Seattle cri-
teria). However, our results do not confirm the in-
crease in the incidence of VOD in the recent years
observed by Coppell et al. [5] (11% vs 15%;
P\.05 when comparing HSCT performed before
or after 1994). In our series, analyzing the cumula-
tive incidence to evaluate competitive events, when
comparing 2 identical periods of 12 years, we
observed a lower CumI since 1997 (11.5% vs
6.5% using Baltimore criteria) attributable in part
to RIC-HSCT (incidence of 2.1%), but also to
a clear reduction in the CumI of VOD among
MAC-HSCT procedures using alternative do-
nors (32.7% vs 10.5%) in this second period.
Probably the improvement of supportive measures,
the increasing use of peripheral blood stem cells,
the selection of donors based on high-resolution
typing for HLA-A, B, C, DRB1, and DQB1 loci,
and the introduction of i.v. busulfan have contrib-
uted to this improvement. Interestingly, when
RIC was applied to patients receiving HSCT
from alternative donors, the CumI of VOD was
similar to that observed with MAC (10.5% vs
7.6%). This observation suggests that the effect of
allo-reactivity on hepatic sinusoids observed in
clinical [6] and experimental approaches [13,14]
acts against the beneficial effect of using less toxic
conditioning.2. Transjugular studies: For the daily management of
these patients, the only usefulness of these studies
was to know in advance the severity of the VOD.
As in most patients with HVGP $10 mmHg, the
death was direct or indirectly related to VOD.
However, being a potentially harmful procedure,
it should only be performed in centers with experi-
ence and in selected cases where it is deemed essen-
tial to obtain a correct differential diagnosis.
3. Risk factors for VOD: Univariate analysis con-
firmed the most relevant previously described risk
factors for this complication as being the patient’s
status, conditioning intensity, previous liver dis-
ease, use of peripheral blood stem cells, T cell
depletion of the graft, and type of donor [1]. We
do not have clear explanation for the slightly higher
incidence of VOD observed in patients with CML,
but this probably results from a combination of fac-
tors, because 10 of 28 received oral Bu before
HSCT, 19 of 28 had a unrelated donor HSCT,
15 of 25 a very intensive conditioning, and all of
them had an active disease at HSCT. In multivari-
ate analysis, a diagnosis of CML, use ofMAC, alter-
native donors, previous liver disease, and a poor
patient status maintained statistical significance,
with MAC being the most predictive variable
(OR 5 7.99). A low incidence of VOD among
RIC recipients has been observed in most reports
of this new type of HSCT, and this fact was
confirmed in a large series of 237 cases using
RIC-HSCT, most of them using Bu therapy [15].
The incidence observed among RIC recipients in
our series was even lower, probably as a conse-
quence of the low incidence of RIC using Bu
(26 of 142). Of note was the fact that all RIC
patients with VOD in our series had several risk
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SCT, poor performance status, and previous liver
disease).
4. VOD evolution: Fortunately, up to 90% of patients
with nonsevere VOD improved after several days
with only supportive measures, or more recently
with DF administration. This is especially true
for patients with only 2 clinical criteria of VOD
following the Seattle criteria, as all showed a rapid
improvement. This observation confirms that the
application of therapeutic measures, other than
water and sodium restriction, should only be con-
sidered in patients fulfilling the Baltimore criteria.
Undoubtedly, the progression to MOF is the best
marker of the severity of the disease. Because the
Seattle classification of severity is retrospective, it
has little relevance for the clinical management of
patients. For that reason, the evolution to MOF
(or a high HVGP if available) must be considered
as the best indicator of severity and predictor of
poor outcome. In our series, we have observed
a clear lower probability of dying from VOD since
1997 (14% vs 36% before), and the only relevant
change in the patients management was the intro-
duction of DF. When comparing mortality rate
by VOD before and after introducing this drug,
the results were significantly different, even
though the severity of the treated cases was similar.
In addition, only 2 of 8 (25%) patients with
MOF receiving DF died of VOD, versus 14 of 18
(78%) who received other treatments (P 5 .007).
This incidence was similar to that observed in
others series of severe cases of VOD not receiving
DF [5]. These data, together with recent observa-
tions showing that DF when used prophylactically
reduces not only the incidence of VOD but also
the incidence ofGVHD [16], that it has a potent an-
tithrombotic effect in human microvascular endo-
thelial cells models [17], and that it produces few
and acceptable secondary effects [18], indicate that
this agent probably could be of great interest in
high-risk patients receiving MAC-HSCT from
unrelated donors.
In summary, our study shows that, although VOD
remains a dreaded early complication of HSCT, tech-
nical progress in recent decades has notably reduced its
incidence and improved the outcome for patients. RIC
has played a major role in this, but the improvement of
results among recipients receiving an unrelatedHSCT
has also contributed. Interestingly, the beneficial effect
of RIC seems to disappear in an unrelated transplant
setting. The use of DF, as well as progress in patient
management, has probably contributed to the clear re-
duction of the morbidity and mortality associated with
VOD, but this can only be confirmed by prospective
randomized studies.ACKNOWLEDGMENTS
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